Oyster Point Pharma

Oyster Point Pharma EBIT

Delisted

The EBIT of Oyster Point Pharma (OYST) as of Nov 18, 2026 is -96.66 M USD. In the previous year, EBIT was -70.99 M USD — a change of 36.15% (lower).

EBIT

-96.66 MUSD

YoY

36.15%

Last updated:

In 2021, Oyster Point Pharma's EBIT was -96.66 M USD, a 36.15% increase from the -70.99 M USD EBIT recorded in the previous year.

The Oyster Point Pharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2019
-47.30 M USD
Jan 1, 2020
-70.99 M USD
Jan 1, 2021
-96.66 M USD
Jan 1, 2022 (e)
-158.53 M USD
Jan 1, 2023 (e)
-85.23 M USD
Jan 1, 2024 (e)
-46.61 M USD
Jan 1, 2025 (e)
-80.59 M USD
Jan 1, 2026 (e)
-109.03 M USD
The Oyster Point Pharma EBIT history
YEAREBITYoY
est-109.03 MUSD+35.30%
est-80.59 MUSD+72.91%
est-46.61 MUSD-45.32%
est-85.23 MUSD-46.24%
est-158.53 MUSD+64.01%
-96.66 MUSD+36.15%
-70.99 MUSD+50.08%
-47.30 MUSD+182.63%
-16.74 MUSD+194.49%
-5.68 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oyster Point Pharma Revenue

Oyster Point Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
0.00 USD
-47.30 M USD
-45.71 M USD
Jan 1, 2020
0.00 USD
-70.99 M USD
-70.52 M USD
Jan 1, 2021
24.54 M USD
-96.66 M USD
-100.66 M USD
Jan 1, 2022 (e)
27.45 M USD
-158.53 M USD
-164.29 M USD
Jan 1, 2023 (e)
99.15 M USD
-85.23 M USD
-83.06 M USD
Jan 1, 2024 (e)
189.86 M USD
-46.61 M USD
-50.53 M USD
Jan 1, 2025 (e)
475.01 M USD
-80.59 M USD
-82.28 M USD
Jan 1, 2026 (e)
1.16 B USD
-109.03 M USD
-113.79 M USD

Oyster Point Pharma Margins

Oyster Point Pharma stock margins

The Oyster Point Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oyster Point Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oyster Point Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
93.79 %
- %
- %
Jan 1, 2020
93.79 %
- %
- %
Jan 1, 2021
93.79 %
-393.88 %
-410.20 %
Jan 1, 2022 (e)
93.79 %
-577.51 %
-598.51 %
Jan 1, 2023 (e)
93.79 %
-85.96 %
-83.77 %
Jan 1, 2024 (e)
93.79 %
-24.55 %
-26.61 %
Jan 1, 2025 (e)
93.79 %
-16.97 %
-17.32 %
Jan 1, 2026 (e)
93.79 %
-9.39 %
-9.80 %

Oyster Point Pharma Stock analysis

What does Oyster Point Pharma do? Oyster Point Pharma Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. The company is headquartered in the San Francisco Bay Area and was founded in 2015. History: Oyster Point Pharma was founded by an experienced team of biologists and pharmaceutical experts. The company was supported by venture capital financing from leading venture capitalists. The founders' goal was to develop innovative therapies for eye diseases. In 2017, the company introduced a pipeline of therapies for various eye diseases based on the stimulation of tear flow, corneal nerves, and neurons. Since then, the company has expanded its pipeline and continues to invest significantly in the research and development of innovative therapies. Business model: Oyster Point Pharma has developed an innovative business model based on the development of therapies for eye diseases. The company utilizes its proprietary technology platform to identify new molecular targets and develop effective therapeutic options. The company works closely with leading scientists and clinics to develop and validate its pipeline of therapies. The company's goal is to develop innovative therapies for eye diseases that help patients improve their vision and quality of life. Segments: Oyster Point Pharma focuses on developing innovative therapies for eye diseases. The company currently has three main products in its pipeline: OC-01, OC-02, and OC-03. OC-01 is a nasal spray based on the stimulation of tear flow. The product is currently in phase 3 clinical development for the treatment of patients with dry eye. Treatment with OC-01 is intended to increase the production and flow of tear fluid, thus relieving symptoms such as dryness, itching, and pain. OC-02 is a gel based on the stimulation of corneal nerves. The product is currently in phase 2 clinical development for the treatment of patients with neurotrophic keratitis. Treatment with OC-02 is intended to promote the regeneration of corneal nerves and accelerate the healing of the cornea. OC-03 is a nasal spray based on the stimulation of neurons in the nasal and oral areas. The product is currently in the preclinical development phase for the treatment of patients with acute glaucoma and has not yet been approved for use in humans. Products: Oyster Point Pharma currently has three main products in its pipeline: OC-01, OC-02, and OC-03. These products aim to develop innovative therapies for various eye diseases. The products utilize proprietary technologies to selectively stimulate tear flow, corneal nerves, and neurons. By developing these innovative therapies, the company aims to improve the vision and quality of life of patients. Summary: Oyster Point Pharma is an innovative biopharmaceutical company focused on the development of therapies for eye diseases. The company has developed a proprietary technology platform for the identification of new molecular targets and the development of effective therapeutic options. The company currently has three main products in its pipeline, aiming to develop innovative therapies for various eye diseases. The company's goal is to develop innovative therapies for eye diseases that help patients improve their vision and quality of life. Oyster Point Pharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Oyster Point Pharma's EBIT

Oyster Point Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Oyster Point Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Oyster Point Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Oyster Point Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Oyster Point Pharma stock

EBIT of Oyster Point Pharma is -96.66 M USD in 2021.

EBIT of Oyster Point Pharma changed from -70.99 M USD to -96.66 M USD, representing a 36.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Oyster Point Pharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Oyster Point Pharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Oyster Point Pharma

All Key Metrics — Oyster Point Pharma